NASDAQ:GLPG - GALAPAGOS NV/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$101.29 +0.85 (+0.85 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$101.29
Today's Range$100.24 - $101.4350
52-Week Range$72.90 - $121.09
Volume50,459 shs
Average Volume114,149 shs
Market Capitalization$5.08 billion
P/E Ratio-38.37
Dividend YieldN/A
Beta1.97

About GALAPAGOS NV/S (NASDAQ:GLPG)

GALAPAGOS NV/S logoGalapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLPG
CUSIPN/A
Phone321-534-2900

Debt

Debt-to-Equity RatioN/A
Current Ratio5.08
Quick Ratio5.08

Price-To-Earnings

Trailing P/E Ratio-38.37
Forward P/E Ratio-25.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$176.13 million
Price / Sales29.47
Cash FlowN/A
Price / CashN/A
Book Value$21.58 per share
Price / Book4.69

Profitability

EPS (Most Recent Fiscal Year)($2.64)
Net Income$-130,780,000.00
Net Margins-86.32%
Return on Equity-14.06%
Return on Assets-10.81%

Miscellaneous

Employees508
Outstanding Shares51,240,000

GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions

What is GALAPAGOS NV/S's stock symbol?

GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."

How were GALAPAGOS NV/S's earnings last quarter?

GALAPAGOS NV/S (NASDAQ:GLPG) posted its quarterly earnings data on Wednesday, April, 25th. The biotechnology company reported ($0.90) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.20) by $0.30. The biotechnology company earned $55.04 million during the quarter, compared to analysts' expectations of $44.77 million. GALAPAGOS NV/S had a negative net margin of 86.32% and a negative return on equity of 14.06%. View GALAPAGOS NV/S's Earnings History.

When is GALAPAGOS NV/S's next earnings date?

GALAPAGOS NV/S is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for GALAPAGOS NV/S.

What price target have analysts set for GLPG?

8 analysts have issued twelve-month price objectives for GALAPAGOS NV/S's stock. Their predictions range from $98.00 to $124.00. On average, they anticipate GALAPAGOS NV/S's share price to reach $115.1667 in the next twelve months. View Analyst Ratings for GALAPAGOS NV/S.

What are Wall Street analysts saying about GALAPAGOS NV/S stock?

Here are some recent quotes from research analysts about GALAPAGOS NV/S stock:
  • 1. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (5/2/2018)
  • 2. BTIG Research analysts commented, "Before-mkt-open on Thursday, Galapagos hosted their 1Q18 financials call and provided an update on clinical programs for 2018. We expect a ramp in clinical efforts for the Cystic Fibrosis portfolio heading into 2H2018, although we agree with the general consensus that the CF effort remains a ‘show-me; story. Beyond CF, we are encouraged by the commitment to the Phase 3 Isabela studies for GLPG1690 in the treatment of Idiopathic Pulmonary Fibrosis (IPF), and remain positive on upcoming data on filgotinib. We reiterate our Buy rating and $118 PT." (4/29/2018)
  • 3. Stifel Nicolaus analysts commented, "Aurinia reported 2Q17 financial results in an after market close press release." (8/11/2017)

Who are some of GALAPAGOS NV/S's key competitors?

Who are GALAPAGOS NV/S's key executives?

GALAPAGOS NV/S's management team includes the folowing people:
  • Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 59)
  • Mr. Bart Filius MBA, CFO & COO (Age 48)
  • Dr. Piet Wigerinck, Chief Scientific Officer (Age 54)
  • Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. Communications
  • Ms. Veronique Deiteren, Head of HR

When did GALAPAGOS NV/S IPO?

(GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Has GALAPAGOS NV/S been receiving favorable news coverage?

Media coverage about GLPG stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. GALAPAGOS NV/S earned a media sentiment score of 0.21 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.65 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are GALAPAGOS NV/S's major shareholders?

GALAPAGOS NV/S's stock is owned by a number of of retail and institutional investors. Top institutional investors include Federated Investors Inc. PA (2.54%), BlackRock Inc. (0.63%), Farallon Capital Management LLC (0.60%), Jane Street Group LLC (0.18%), Dorsey Wright & Associates (0.18%) and Alps Advisors Inc. (0.13%). View Institutional Ownership Trends for GALAPAGOS NV/S.

Which major investors are selling GALAPAGOS NV/S stock?

GLPG stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Jane Street Group LLC, BlackRock Inc., Eventide Asset Management LLC, Millennium Management LLC, UBS Group AG and US Bancorp DE. View Insider Buying and Selling for GALAPAGOS NV/S.

Which major investors are buying GALAPAGOS NV/S stock?

GLPG stock was acquired by a variety of institutional investors in the last quarter, including Dorsey Wright & Associates, Farallon Capital Management LLC, Alps Advisors Inc., Landscape Capital Management L.L.C., DekaBank Deutsche Girozentrale, Victory Capital Management Inc., Employees Retirement System of Texas and Aperio Group LLC. View Insider Buying and Selling for GALAPAGOS NV/S.

How do I buy shares of GALAPAGOS NV/S?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GALAPAGOS NV/S's stock price today?

One share of GLPG stock can currently be purchased for approximately $101.29.

How big of a company is GALAPAGOS NV/S?

GALAPAGOS NV/S has a market capitalization of $5.08 billion and generates $176.13 million in revenue each year. The biotechnology company earns $-130,780,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. GALAPAGOS NV/S employs 508 workers across the globe.

How can I contact GALAPAGOS NV/S?

GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]


MarketBeat Community Rating for GALAPAGOS NV/S (GLPG)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  404
MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GALAPAGOS NV/S (NASDAQ:GLPG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for GALAPAGOS NV/S in the last 12 months. Their average twelve-month price target is $115.1667, suggesting that the stock has a possible upside of 13.70%. The high price target for GLPG is $124.00 and the low price target for GLPG is $98.00. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.75
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $115.1667$115.1667$115.1667$115.1667
Price Target Upside: 13.70% upside0.16% upside0.16% upside23.32% upside

GALAPAGOS NV/S (NASDAQ:GLPG) Consensus Price Target History

Price Target History for GALAPAGOS NV/S (NASDAQ:GLPG)

GALAPAGOS NV/S (NASDAQ:GLPG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/29/2018BTIG ResearchReiterated RatingBuy$118.00LowView Rating Details
10/29/2017Stifel NicolausReiterated RatingBuy$120.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$92.00 ➝ $123.00N/AView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$98.00MediumView Rating Details
8/11/2017NomuraBoost Price TargetBuy$108.00 ➝ $124.00LowView Rating Details
8/10/2017CowenReiterated RatingBuyMediumView Rating Details
7/7/2017Janney Montgomery ScottUpgradeSell ➝ NeutralLowView Rating Details
6/22/2017InstinetReiterated RatingBuy$121.00 ➝ $108.00LowView Rating Details
10/18/2016Goldman Sachs GroupUpgradeNeutral ➝ BuyN/AView Rating Details
6/17/2016Credit Suisse GroupReiterated RatingHold$48.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

GALAPAGOS NV/S (NASDAQ:GLPG) Earnings History and Estimates Chart

Earnings by Quarter for GALAPAGOS NV/S (NASDAQ:GLPG)

GALAPAGOS NV/S (NASDAQ:GLPG) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.70)($0.70)($0.70)
Q3 20181($0.70)($0.70)($0.70)
Q4 20181($0.80)($0.80)($0.80)

GALAPAGOS NV/S (NASDAQ GLPG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018        
4/25/2018Q1 2018($1.20)($0.90)$44.77 million$55.04 millionViewN/AView Earnings Details
2/22/2018Q4 2017($0.67)($0.69)$42.84 million$58.37 millionViewN/AView Earnings Details
10/24/2017Q3 2017($0.78)($0.85)$15.85 million$39.16 millionViewN/AView Earnings Details
7/31/2017Q2 2017($0.91)($0.81)$14.80 million$36.45 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.50)($0.31)$31.81 million$42.51 millionViewN/AView Earnings Details
2/24/2017Q4 2016$0.22$1.05$77.67 million$93.43 millionViewN/AView Earnings Details
10/26/2016Q3 2016($0.82)($0.58)$28.50 million$18.16 millionViewN/AView Earnings Details
7/29/2016Q2 2016($0.11)$32.38 millionViewN/AView Earnings Details
4/28/2016Q1 2016$0.87$16.33 millionViewN/AView Earnings Details
3/23/2016Q4 2015($1.71)$14.84 millionViewN/AView Earnings Details
11/13/2015Q3($0.80)$11.46 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

GALAPAGOS NV/S (NASDAQ:GLPG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

GALAPAGOS NV/S (NASDAQ GLPG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.91%
Institutional Ownership Percentage: 17.36%
Insider Trading History for GALAPAGOS NV/S (NASDAQ:GLPG)
Institutional Ownership by Quarter for GALAPAGOS NV/S (NASDAQ:GLPG)

GALAPAGOS NV/S (NASDAQ GLPG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

GALAPAGOS NV/S (NASDAQ GLPG) News Headlines

Source:
DateHeadline
Galapagos NV: GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATSGalapagos NV: GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
www.finanznachrichten.de - May 21 at 4:33 PM
GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATSGLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
finance.yahoo.com - May 20 at 5:01 PM
Galápagos NV (GLPG) Receives Average Recommendation of "Hold" from BrokeragesGalápagos NV (GLPG) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 20 at 3:33 PM
How Should You Think About Galapagos NV’s (AMS:GLPG) Risks?How Should You Think About Galapagos NV’s (AMS:GLPG) Risks?
finance.yahoo.com - May 18 at 9:56 AM
Galápagos NV (GLPG) Expected to Announce Quarterly Sales of $51.73 MillionGalápagos NV (GLPG) Expected to Announce Quarterly Sales of $51.73 Million
www.americanbankingnews.com - May 12 at 2:20 AM
-$0.92 Earnings Per Share Expected for Galápagos NV (GLPG) This Quarter-$0.92 Earnings Per Share Expected for Galápagos NV (GLPG) This Quarter
www.americanbankingnews.com - May 10 at 7:22 PM
Galápagos (GLPG) Upgraded at ValuEngineGalápagos (GLPG) Upgraded at ValuEngine
www.americanbankingnews.com - May 3 at 5:12 PM
A quicker way to see the Galapagos Islands without missing the wildlifeA quicker way to see the Galapagos Islands without missing the wildlife
www.latimes.com - May 3 at 4:33 PM
Research Analysts Issue Forecasts for Galápagos NVs Q2 2018 Earnings (GLPG)Research Analysts Issue Forecasts for Galápagos NV's Q2 2018 Earnings (GLPG)
www.americanbankingnews.com - May 3 at 8:17 AM
Galápagos (GLPG) Upgraded to Hold by Zacks Investment ResearchGalápagos (GLPG) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - May 2 at 11:11 AM
Jefferies Group Equities Analysts Boost Earnings Estimates for Galápagos NV (GLPG)Jefferies Group Equities Analysts Boost Earnings Estimates for Galápagos NV (GLPG)
www.americanbankingnews.com - May 2 at 10:22 AM
BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patientsBRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients
www.reuters.com - May 2 at 9:15 AM
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis ...Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis ...
www.nasdaq.com - May 1 at 4:31 PM
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patientsGalapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
finance.yahoo.com - May 1 at 4:31 PM
Galápagos (GLPG) Downgraded by BidaskClub to SellGalápagos (GLPG) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - May 1 at 9:08 AM
BTIG Research Reiterates "Buy" Rating for Galápagos (GLPG)BTIG Research Reiterates "Buy" Rating for Galápagos (GLPG)
www.americanbankingnews.com - April 29 at 9:17 AM
GALAPAGOS NVGALAPAGOS NV
www.streetinsider.com - April 28 at 9:42 AM
Vertex Slips As FDA Delays Cystic Fibrosis Drug — But There's A Silver LiningVertex Slips As FDA Delays Cystic Fibrosis Drug — But There's A Silver Lining
finance.yahoo.com - April 27 at 4:34 PM
BRIEF-Galapagos Presents Strong Disease-Modifying Effects With Glpg1972 At Oarsi 2018BRIEF-Galapagos Presents Strong Disease-Modifying Effects With Glpg1972 At Oarsi 2018
www.reuters.com - April 27 at 9:48 AM
Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018
finance.yahoo.com - April 27 at 9:48 AM
Galapagos (GLPG) CEO Onno van de Stolpe on Q1 2018 Results - Earnings Call TranscriptGalapagos' (GLPG) CEO Onno van de Stolpe on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 4:34 PM
BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million EurosBRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros
www.reuters.com - April 26 at 9:07 AM
Galápagos NV (GLPG) Receives Consensus Recommendation of "Hold" from AnalystsGalápagos NV (GLPG) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 25 at 5:30 PM
Galapagos reports first quarter 2018 resultsGalapagos reports first quarter 2018 results
finance.yahoo.com - April 25 at 4:44 PM
What Should Investors Know About Galapagos NV’s (AMS:GLPG) Earnings Outlook?What Should Investors Know About Galapagos NV’s (AMS:GLPG) Earnings Outlook?
finance.yahoo.com - April 25 at 9:21 AM
The Largest and Smallest Penguins in the WorldThe Largest and Smallest Penguins in the World
247wallst.com - April 24 at 4:48 PM
Form 6-K GALAPAGOS NV For: Apr 24Form 6-K GALAPAGOS NV For: Apr 24
www.streetinsider.com - April 24 at 4:48 PM
Gal�pagos (GLPG) Set to Announce Earnings on WednesdayGal�pagos (GLPG) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 21 at 9:20 AM
Gal�pagos (GLPG) Rating Reiterated by BTIG ResearchGal�pagos (GLPG) Rating Reiterated by BTIG Research
www.americanbankingnews.com - April 20 at 8:00 PM
Galapagos creates new warrant planGalapagos creates new warrant plan
finance.yahoo.com - April 19 at 4:46 PM
Galapagos on go with Phase 3 program for GLPG1690 in IPFGalapagos on go with Phase 3 program for GLPG1690 in IPF
seekingalpha.com - April 12 at 4:34 PM
Galapagos announces ISABELA Phase 3 program in IPFGalapagos announces ISABELA Phase 3 program in IPF
finance.yahoo.com - April 12 at 4:34 PM
Factors of Influence in 2018, Key Indicators and Opportunity within Galapagos NV, BanColombia S.A, Fanhua, Landec, Green Brick Partners, and Core-Mark Holding — New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within Galapagos NV, BanColombia S.A, Fanhua, Landec, Green Brick Partners, and Core-Mark Holding — New Research Emphasizes Economic Growth
finance.yahoo.com - April 12 at 10:09 AM
Gal�pagos NV (GLPG) Given Average Rating of "Hold" by BrokeragesGal�pagos NV (GLPG) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 31 at 3:34 PM
Zacks Investment Research Upgrades Gal�pagos (GLPG) to "Hold"Zacks Investment Research Upgrades Gal�pagos (GLPG) to "Hold"
www.americanbankingnews.com - March 31 at 6:52 AM
Is Galapagos NV (AMS:GLPG) A Financially Strong Company?Is Galapagos NV (AMS:GLPG) A Financially Strong Company?
finance.yahoo.com - March 28 at 9:33 AM
Gal�pagos (GLPG) Upgraded to "Hold" at BidaskClubGal�pagos (GLPG) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 28 at 12:34 AM
Galapagos (GLPG) Lifted to "Hold" at ValuEngineGalapagos (GLPG) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - March 25 at 5:52 PM
Galapagos NV: Publication of the annual report and invitation to the annual shareholders meetingGalapagos NV: Publication of the annual report and invitation to the annual shareholders' meeting
www.finanznachrichten.de - March 24 at 9:46 AM
Publication of the annual report and invitation to the annual shareholders meetingPublication of the annual report and invitation to the annual shareholders' meeting
finance.yahoo.com - March 23 at 4:34 PM
Galapagos NV (GLPG) Increases Share Capital Through Warrant Exercises - StreetInsider.comGalapagos NV (GLPG) Increases Share Capital Through Warrant Exercises - StreetInsider.com
www.streetinsider.com - March 21 at 4:39 PM
Galapagos NV (GLPG) Increases Share Capital Through Warrant ExercisesGalapagos NV (GLPG) Increases Share Capital Through Warrant Exercises
www.streetinsider.com - March 21 at 10:26 AM
Galapagos NV (GLPG) Receives Consensus Rating of "Hold" from AnalystsGalapagos NV (GLPG) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 6 at 3:22 PM
Arrowstreet Capital Limited Partnership Takes $3.65 Million Position in Galapagos NV (GLPG)Arrowstreet Capital Limited Partnership Takes $3.65 Million Position in Galapagos NV (GLPG)
www.americanbankingnews.com - March 6 at 4:38 AM
BidaskClub Downgrades Galapagos (GLPG) to HoldBidaskClub Downgrades Galapagos (GLPG) to Hold
www.americanbankingnews.com - March 3 at 11:42 PM
FY2018 Earnings Estimate for Galapagos NV (GLPG) Issued By Jefferies GroupFY2018 Earnings Estimate for Galapagos NV (GLPG) Issued By Jefferies Group
www.americanbankingnews.com - February 28 at 12:04 PM
Galapagos NV: Galapagos delivered in 2017Galapagos NV: Galapagos delivered in 2017
www.finanznachrichten.de - February 23 at 9:14 AM
Galapagos delivered in 2017Galapagos delivered in 2017
finance.yahoo.com - February 22 at 4:56 PM
MorphoSys and Galapagos Present Results from a...MorphoSys and Galapagos Present Results from a...
www.benzinga.com - February 17 at 4:22 PM
Galapagos and MorphoSys present results from a...Galapagos and MorphoSys present results from a...
www.benzinga.com - February 17 at 8:54 AM

SEC Filings

GALAPAGOS NV/S (NASDAQ:GLPG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GALAPAGOS NV/S (NASDAQ:GLPG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GALAPAGOS NV/S (NASDAQ GLPG) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.